Roche (RHHBY) Stock Price, News & Analysis

Company Overview

Roche Holding AG is a Switzerland-based healthcare company that develops and provides pharmaceutical products and diagnostic solutions. Founded in 1896 and headquartered in Basel, Roche operates through two complementary divisions: Pharmaceuticals and Diagnostics.

The Pharmaceuticals division focuses on medicines for oncology, immunology, neuroscience, ophthalmology, hematology and other therapeutic areas. Its portfolio includes treatments such as Ocrevus, Hemlibra, Perjeta, Tecentriq and Vabysmo. Roche’s Diagnostics division supplies laboratory instruments, tests and digital solutions used in disease detection, monitoring and treatment decisions across hospitals, clinics and medical laboratories.

Roche serves healthcare providers and patients in markets around the world. The company has also maintained a long-standing relationship with Genentech, which became a wholly owned member of the Roche Group in 2009 and serves as Roche’s U.S. biotechnology center. Thomas Schinecker has served as Roche’s chief executive officer since 2023, while Severin Schwan is chairman of the board.

Key Stats

• Today's Range: $54.74 to $55.87
• 50-Day Range: $51.00 to $58.47
• 52-Week Range: $39.50 to $60.85
• Volume: 634,213 shs
• Average Volume: 2.29 million shs
• Market Capitalization: $349.03 billion
• P/E Ratio: N/A
• Dividend Yield: 1.77%
• Price Target: $60.00
• Consensus Rating: Moderate Buy

Roche Stock Analysis - MarketRank™

Roche scored higher than 70% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Roche has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 6 buy ratings, 6 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Roche is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Roche has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 7.84%

Earnings Growth

Earnings for Roche are expected to grow by 7.84% in the coming year, from $3.06 to $3.30 per share.

Price to Earnings Growth Ratio

Roche has a PEG Ratio of 3.53. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Roche has a P/B Ratio of 7.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.05% of the float of Roche has been sold short.

Short Interest Ratio / Days to Cover

Roche has a short interest ratio ("days to cover") of 0.84, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Roche has recently increased by 16.07%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Roche pays a meaningful dividend of 1.76%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Roche does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Roche will have a dividend payout ratio of 29.39% next year. This indicates that Roche will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.66

News Sentiment

Roche has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 26 news articles for Roche this week, compared to 7 articles on an average week.

Search Interest

Only 6 people have searched for RHHBY on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

5 people have added Roche to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Roche insiders have not sold or bought any company stock.

Percentage Held by Institutions

Roche has minimal institutional ownership at this time.

Company Calendar

• Today: 9/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:RHHBY
• CIK: N/A
• Web: www.roche.com
• Phone: (161) 688-1111
• Fax: 41-0-61-691-9391
• Employees: 103,249
• Year Founded: 1896

Price Target and Rating

• Average Price Target for Roche: $60.00
• High Price Target: $63.00
• Low Price Target: $57.00
• Potential Upside/Downside: +9.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 17.91
• P/E Growth: 3.53
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.72
• Current Ratio: 1.38
• Quick Ratio: 1.12

Sales & Book Value

• Annual Sales: $76.45 billion
• Price / Sales: 4.57
• Cash Flow: $3.57 per share
• Price / Cash Flow: 15.36
• Book Value: $7.18 per share
• Price / Book: 7.63

Miscellaneous

• Outstanding Shares: 6,370,540,000
• Free Float: N/A
• Market Cap: $349.11 billion
• Optionable: Not Optionable
• Beta: 0.48